Micromet buys out MedImmune's stake in anti-cancer compound
Micromet secured rights to develop and commercialize cancer drug blinatumomab in North America after buying out MedImmune's remaining rights to the treatment. The biotech firm plans to conduct clinical studies of the drug next year.
American City Business Journals | 11/05
This story published in BIO SmartBrief on 11/06/2009
More from SmartBrief:
Rosetta, Warnex sign Canadian distribution deal
Tuesday, August 11, 2009
Catalyst licenses technology to MedImmune for potential $195M
Monday, July 13, 2009
Sebelius announces FDA approval of H1N1 flu vaccines
Wednesday, September 16, 2009
Get stories like these delivered daily for FREE:
|
BIO SmartBrief
Designed specifically for biotechnology industry professionals like you, BIO SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important biotech issues. Learn more |
|